Skip to main content

Advertisement

SpringerLink
Log in

Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France

  • Commentary
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

This study was undertaken to assess the previously unevaluated safety and feasibility of oxaliplatin-desensitization procedure add a French ambulatory cancer unit, which is a current topic in oncology. Our findings demonstrated that oxaliplatin-desensitization was safe and feasible in our ambulatory cancer unit. In routine practice, all these procedures are done on an inpatient basis starting at least the day before. Those results could change oncological practices in France and improve patients’ quality of life and lower costs associated with inpatient administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351

    Article  Google Scholar 

  2. Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN (2009) Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 8(2):106–109

    Article  CAS  PubMed  Google Scholar 

  3. Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, Di Marco MC, Biasco G (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89(3):477–481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hong DI, Dioun AF (2014) Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children. J Allergy Clin Immunol Pract 2(1):13–19 quiz 20

    Article  PubMed  Google Scholar 

  5. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122(3):574–580

    Article  CAS  PubMed  Google Scholar 

  6. Wong JT, Ling M, Patil S, Banerji A, Long A (2014) Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2(1):40–45

    Article  PubMed  Google Scholar 

  7. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Protocol Development (2010) | CTEP

  8. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, Gomez de Salazar E, Alvarez-Cuesta E (2013) Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 68(7):853–861

    Article  CAS  PubMed  Google Scholar 

  9. Le Roy F, Rigault E, Regnault D, Hubert N, Burtin P, Hollebecque A, Malka D, Boige V, Ducreux M (2018) Oxaliplatin desensitization after hypersensitivity reaction: a single-center experience on more than 300 procedures. J Clin Oncol 36(4_suppl):610–610

    Article  Google Scholar 

Download references

Acknowledgments

We acknowledge Janet Jacobson, an English-speaking American scientist, for her review of our clinical report.

Author information

Authors and Affiliations

  1. Ambulatory Cancer Unit, CHU Reims, Robert-Debré Hospital, Avenue rue du Général Koenig, 51092, Reims Cedex, France

    Damien Botsen, Elise Lepoix, Camille Mazza, Mathilde Brasseur, Florian Slimano & Olivier Bouché

  2. Department of Gastroenterology and Digestive Oncology, Reims University Hospital, Reims, France

    Damien Botsen, Mathilde Brasseur & Olivier Bouché

  3. Department of Immunoallergy and Dermatology, CHU Reims, Robert-Debré Hospital, Avenue General Koenig, Reims, France

    Anne Grange

  4. Department of Pharmacy, CHU Reims, Robert-Debré Hospital, Avenue General Koenig, Reims, France

    Florian Slimano

Authors
  1. Damien Botsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elise Lepoix
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Camille Mazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mathilde Brasseur
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anne Grange
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Florian Slimano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Olivier Bouché
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Damien Botsen.

Ethics declarations

Research involving human participants and/or animals

For this type of study format consent is not required.

Informed consent

For this type of study format consent is not required.

Conflict of interest

Damien Botsen reports personal fees from Pierre Fabre and non-financial support from GlaxoSmithKline, Novartis, Chugai, and Amgen outside the submitted work.

Camille Mazza reports personal fees from Pierre Fabre outside the submitted work.

Mathilde Brasseur reports personal fees from Bayer and non-financial support from Pierre Fabre, Novartis, Amgen, Roche, and AbbVie outside the submitted work.

Olivier Bouche reports grants from Roche, personal fees from Roche, grants from Pierre Fabre, personal fees from Pierre Fabre, personal fees from Amgen, personal fees from Bayer, personal fees from Lilly, personal fees from Merck, personal fees from Novartis, outside the submitted work.

Elise Lepoix, Florian Slimano, and Anne Grange: none.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Botsen, D., Lepoix, E., Mazza, C. et al. Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France. Support Care Cancer 27, 3179–3182 (2019). https://doi.org/10.1007/s00520-019-04863-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-019-04863-5

Keywords

Search

Navigation